(PGNY) Progyny - Ratings and Ratios
Fertility, Benefits, Pharmacy,
PGNY EPS (Earnings per Share)
PGNY Revenue
Description: PGNY Progyny August 10, 2025
Progyny Inc (NASDAQ:PGNY) is a US-based healthcare services company. The firms business model is centered around providing fertility benefits to employees, which is a rapidly growing segment in the healthcare industry.
Key drivers of PGNYs financial performance include the increasing demand for fertility services, the growing awareness and acceptance of fertility treatments, and the companys ability to negotiate favorable pricing with providers. The companys revenue growth is likely driven by the increasing adoption of its services by employers and health plans.
To evaluate PGNYs performance, we can look at key performance indicators (KPIs) such as revenue growth rate, member acquisition rate, and average revenue per member. The companys ability to retain members and increase revenue per member will be crucial in driving long-term growth. Additionally, metrics such as the number of treatment cycles, live birth rates, and patient satisfaction will provide insights into the companys operational performance.
From a financial perspective, PGNYs valuation multiples, such as the P/E ratio of 39.46, suggest that the market is pricing in significant growth expectations. The forward P/E ratio of 14.43 indicates a potential decrease in earnings growth rate in the future. The companys Return on Equity (RoE) of 11.80% is a respectable metric, indicating that PGNY is generating profits from shareholder equity.
Economic drivers that may impact PGNYs business include changes in healthcare policy, the competitive landscape of the fertility benefits market, and demographic trends such as the increasing age of first-time mothers. The companys ability to adapt to these changes and maintain its competitive edge will be crucial in driving long-term success.
PGNY Stock Overview
| Market Cap in USD | 1,609m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2019-10-25 |
PGNY Stock Ratings
| Growth Rating | -35.7% |
| Fundamental | 75.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 18.7% |
| Analyst Rating | 3.80 of 5 |
PGNY Dividends
Currently no dividends paidPGNY Growth Ratios
| Growth Correlation 3m | -91.8% |
| Growth Correlation 12m | 33.5% |
| Growth Correlation 5y | -83.6% |
| CAGR 5y | -21.98% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.32 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.69 |
| Sharpe Ratio 12m | 1.00 |
| Alpha | -5.31 |
| Beta | 1.344 |
| Volatility | 44.10% |
| Current Volume | 1891.8k |
| Average Volume 20d | 1241.7k |
| Stop Loss | 17.2 (-4.5%) |
| Signal | 0.20 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (53.1m TTM) > 0 and > 6% of Revenue (6% = 74.5m TTM) |
| FCFTA 0.25 (>2.0%) and ΔFCFTA 0.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 30.11% (prev 31.50%; Δ -1.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.27 (>3.0%) and CFO 202.0m > Net Income 53.1m (YES >=105%, WARN >=100%) |
| Net Debt (-107.0m) to EBITDA (82.7m) ratio: -1.29 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (89.6m) change vs 12m ago -8.38% (target <= -2.0% for YES) |
| Gross Margin 22.34% (prev 22.08%; Δ 0.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 170.2% (prev 162.2%; Δ 8.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.44 (EBITDA TTM 82.7m / Interest Expense TTM -10.6m) >= 6 (WARN >= 3) |
Altman Z'' 5.46
| (A) 0.49 = (Total Current Assets 594.4m - Total Current Liabilities 220.4m) / Total Assets 761.0m |
| (B) 0.23 = Retained Earnings (Balance) 176.5m / Total Assets 761.0m |
| (C) 0.11 = EBIT TTM 78.7m / Avg Total Assets 729.8m |
| (D) 0.72 = Book Value of Equity 176.7m / Total Liabilities 245.9m |
| Total Rating: 5.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.04
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 14.31% = 5.0 |
| 3. FCF Margin 15.31% = 3.83 |
| 4. Debt/Equity 0.05 = 2.50 |
| 5. Debt/Ebitda -1.29 = 2.50 |
| 6. ROIC - WACC (= -0.01)% = -0.02 |
| 7. RoE 11.55% = 0.96 |
| 8. Rev. Trend 90.15% = 6.76 |
| 9. EPS Trend 50.05% = 2.50 |
What is the price of PGNY shares?
Over the past week, the price has changed by +19.56%, over one month by +11.85%, over three months by -2.99% and over the past year by +35.33%.
Is Progyny a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PGNY is around 13.61 USD . This means that PGNY is currently overvalued and has a potential downside of -24.43%.
Is PGNY a buy, sell or hold?
- Strong Buy: 4
- Buy: 0
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PGNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.3 | 56.9% |
| Analysts Target Price | 28.3 | 56.9% |
| ValueRay Target Price | 15.5 | -14% |
PGNY Fundamental Data Overview November 02, 2025
P/E Trailing = 31.7119
P/E Forward = 10.4275
P/S = 1.2953
P/B = 3.4308
Beta = 1.344
Revenue TTM = 1.24b USD
EBIT TTM = 78.7m USD
EBITDA TTM = 82.7m USD
Long Term Debt = 25.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.12m USD (from shortTermDebt, last quarter)
Debt = 25.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -107.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.33b USD (1.61b + Debt 25.5m - CCE 305.1m)
Interest Coverage Ratio = -7.44 (Ebit TTM 78.7m / Interest Expense TTM -10.6m)
FCF Yield = 14.31% (FCF TTM 190.2m / Enterprise Value 1.33b)
FCF Margin = 15.31% (FCF TTM 190.2m / Revenue TTM 1.24b)
Net Margin = 4.28% (Net Income TTM 53.1m / Revenue TTM 1.24b)
Gross Margin = 22.34% ((Revenue TTM 1.24b - Cost of Revenue TTM 964.5m) / Revenue TTM)
Gross Margin QoQ = 23.72% (prev 23.39%)
Tobins Q-Ratio = 1.75 (Enterprise Value 1.33b / Total Assets 761.0m)
Interest Expense / Debt = 2.77% (Interest Expense 706.0k / Debt 25.5m)
Taxrate = 36.80% (9.96m / 27.1m)
NOPAT = 49.7m (EBIT 78.7m * (1 - 36.80%))
Current Ratio = 2.70 (Total Current Assets 594.4m / Total Current Liabilities 220.4m)
Debt / Equity = 0.05 (Debt 25.5m / totalStockholderEquity, last quarter 515.0m)
Debt / EBITDA = -1.29 (Net Debt -107.0m / EBITDA 82.7m)
Debt / FCF = -0.56 (Net Debt -107.0m / FCF TTM 190.2m)
Total Stockholder Equity = 459.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.98% (Net Income 53.1m / Total Assets 761.0m)
RoE = 11.55% (Net Income TTM 53.1m / Total Stockholder Equity 459.8m)
RoCE = 16.21% (EBIT 78.7m / Capital Employed (Equity 459.8m + L.T.Debt 25.5m))
RoIC = 10.81% (NOPAT 49.7m / Invested Capital 459.8m)
WACC = 10.83% (E(1.61b)/V(1.63b) * Re(10.97%) + D(25.5m)/V(1.63b) * Rd(2.77%) * (1-Tc(0.37)))
Discount Rate = 10.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -2.53%
[DCF Debug] Terminal Value 72.52% ; FCFE base≈182.5m ; Y1≈225.1m ; Y5≈384.1m
Fair Price DCF = 47.30 (DCF Value 4.07b / Shares Outstanding 86.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 50.05 | EPS CAGR: -30.91% | SUE: -1.01 | # QB: 0
Revenue Correlation: 90.15 | Revenue CAGR: 19.20% | SUE: 0.99 | # QB: 3
Additional Sources for PGNY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle